SCNI SCNI
Company Profile ↓Company Overview
SCNI (SCNI) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -83.44% |
| 6 Months: | -75.25% |
| 3 Months: | -60.00% |
| 1 Month: | -3.10% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.24 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 86.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Mar 2023 |
|---|---|---|
| Operating Income | -2.62M | -3.19M |
| Net Income | -2.48M | -3.52M |
| Diluted EPS | -0.00 | -0.00 |
| R&D Expense | 1.16M | 2.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 |
|---|---|---|
| Operating Income | -10.86M | -11.06M |
| Net Income | -8.21M | -5.80M |
| Diluted EPS | -0.02 | -0.01 |
| R&D Expense | 3.25M | 5.76M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 |
|---|---|---|---|
| Total Assets | - | 32.04M | 27.07M |
| Total Equity | -15.04M | 982.00K | -1.76M |
| Cash & Equivalents | - | 17.37M | 14.07M |
| Current Liabilities | - | 2.44M | 2.34M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 |
|---|---|---|
| Operating Cash Flow | -7.43M | -7.26M |
| Investing Cash Flow | -139.00K | -836.00K |
| Financing Cash Flow | 21.43M | 6.78M |
| Capital Expenditure | -139.00K | -836.00K |
| Free Cash Flow | -7.57M | -8.10M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | -835.6% | 329.3% |
| ROCE % | -36.7% | -44.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SCNI
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three m…
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company focused on inflammation and immunology, today announced that members of its leadership team will lead a strategic roundtable discussion a…
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics and the owner of Scinai Biopharma Services Ltd., a contract d…
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation and immunology therapeutics and operating a growing CDMO business, today announced the completion of a strategic…
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to combine therapeutic innovation with revenue-generating drug development and man…
SCNI — Frequently Asked Questions
What is the current share price of SCNI?
As of 2026-08-05 17:25 PDT, SCNI trades at $0.25 on NASDAQ/NYSE. Its 52-week range is $0.23 to $1.82.
What is the P/E ratio of SCNI?
SCNI trades at a trailing price-to-earnings (P/E) ratio of -25.00.
Is SCNI a good stock to buy?
This page provides a data-driven analysis of SCNI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.